Alkermes CEO Transition Signals Strategic Shift in Neuroscience Focus
Event summary
- Richard Pops to retire as Alkermes CEO on July 31, 2026, after 35 years of leadership.
- Blair Jackson, current EVP and COO, appointed as successor effective August 1, 2026.
- Pops will remain as Chairman and advisor post-transition.
- Alkermes generated $1.5B in annual revenue, driven by neuroscience-focused commercial portfolio.
- Recent Avadel acquisition expanded sleep medicine capabilities.
The big picture
Alkermes' leadership transition comes as the company solidifies its position in neuroscience drug development, particularly in sleep medicine following the Avadel acquisition. The shift from Pops to Jackson marks a generational change, with Jackson's operational experience likely to focus on integrating recent acquisitions and advancing the orexin agonism pipeline. The company's $1.5B revenue base provides a strong foundation, but the success of its late-stage candidates will be critical for sustained growth.
What we're watching
- Pipeline Execution
- How Alkermes will advance its orexin agonism pipeline, particularly alixorexton, under new leadership.
- Integration Challenges
- Whether the Avadel acquisition will be fully leveraged to enhance Alkermes' sleep medicine capabilities.
- Leadership Continuity
- The pace at which Jackson can maintain strategic momentum while transitioning from Pops' long tenure.
Related topics